Caption Management, LLC Ultragenyx Pharmaceutical Inc. Put Options Transaction History

Caption Management, LLC

14 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $1.21 Million - $1.78 Million	30,000 New	30,000 $1.67 Million
Q1 2024 May 15, 2024	SELL	$43.02 - $53.69 $275,328 - $343,616	-6,400 Reduced 21.33%	23,600 $1.1 Million
Q4 2023 Feb 14, 2024	BUY	$31.73 - $49.19 $237,975 - $368,925	7,500 Added 33.33%	30,000 $1.43 Million
Q3 2023 Nov 14, 2023	SELL	$34.92 - $46.66 $2.36 Million - $3.15 Million	-67,500 Reduced 75.0%	22,500 $802,000
Q2 2023 Aug 14, 2023	BUY	$37.35 - $52.15 $2.24 Million - $3.13 Million	60,000 Added 200.0%	90,000 $4.15 Million
Q1 2023 May 15, 2023	BUY	$36.99 - $48.71 $369,900 - $487,100	10,000 Added 50.0%	30,000 $1.2 Million
Q4 2022 Feb 14, 2023	SELL	$33.72 - $46.33 $2.1 Million - $2.89 Million	-62,400 Reduced 75.73%	20,000 $926,000
Q3 2022 Nov 14, 2022	SELL	$39.96 - $66.14 $3.2 Million - $5.3 Million	-80,200 Reduced 49.32%	82,400 $3.41 Million
Q2 2022 Aug 15, 2022	BUY	$45.8 - $85.4 $5.91 Million - $11 Million	129,100 Added 385.37%	162,600 $9.7 Million
Q1 2022 May 13, 2022	BUY	$62.2 - $84.4 $2.08 Million - $2.83 Million	33,500 New	33,500 $2.43 Million
Q2 2021 Aug 16, 2021	SELL	$92.19 - $115.71 $2.3 Million - $2.89 Million	-25,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$106.9 - $167.73 $213,800 - $335,460	-2,000 Reduced 7.41%	25,000 $2.85 Million
Q3 2020 Nov 16, 2020	SELL	$72.98 - $90.0 $2.15 Million - $2.66 Million	-29,500 Reduced 52.21%	27,000 $2.22 Million
Q2 2020 Aug 14, 2020	BUY	$46.91 - $78.22 $2.65 Million - $4.42 Million	56,500 New	56,500 $4.42 Million

325

85.6M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.06B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.